Nazibur Rahman

Robert Blum

- Aytu BioPharma recently concluded **fiscal year 2025** with consistent positive **adjusted EBITDA in the $9 to $10 million range** over the past three years, following a strategic realignment to focus on its prescription business.  **[1385818_2162743_1]** 
- The company is preparing for the **fiscal 2026 launch of Exua**, an FDA-approved antidepressant for major depressive disorder, with commercial launch anticipated in **calendar Q4 2025**.  **[1385818_2162743_2]** **[1385818_2162743_3]** 
- Exua is positioned as a highly differentiated product due to its **unique mechanism of action** (5-HT1A receptor agonism), which avoids common side effects like sexual dysfunction and weight gain, addressing a market of over **20 million Americans**.  **[1385818_2162743_3]** **[1385818_2162743_7]** 
- Aytu's existing ADHD portfolio provides a solid revenue base of **over $66 million in trailing 12-month net revenues**, which, along with **over $30 million in cash as of June 30**, will fund the Exua launch.  **[1385818_2162743_4]** **[1385818_2162743_9]**

Aytu BioPharma Prepares for Exua Launch Following Strong Fiscal 2025 Performance

- AYTU Biopharma reported **$66.4 million in revenue** and **$9.2 million in adjusted EBITDA** for the fiscal year ended June 30, 2025, marking its third consecutive year of positive adjusted EBITDA.  **[1385818_2157830_6]** 
- The company is preparing for the launch of **ExuA**, an FDA-approved novel treatment for major depressive disorder (MDD), with anticipated sales to wholesalers by **November/December 2025** and meaningful revenue expected in **Q2 2026**.  **[1385818_2157830_2]** **[1385818_2157830_5]** 
- ExuA is differentiated by the **absence of sexual dysfunction and weight gain side effects**, which are common with existing MDD treatments, and targets a **$22 billion MDD market**.  **[1385818_2157830_1]** 
- To support the ExuA launch, AYTU raised **$15 million net in June 2025** and plans to spend approximately **$10 million in operating expenses** for the launch, with **$6-7 million** being one-time costs.  **[1385818_2157830_0]** **[1385818_2157830_5]** **[1385818_2157830_6]** 
- The company's base business, focused on ADHD and pediatric products, generated **$58 million from ADHD** and expects to mitigate generic competition through its **RxConnect program** and the recent launch of its own generic product on **September 2**.  **[1385818_2157830_0]** **[1385818_2157830_3]**

AYTU Biopharma Reports FY25 Results and Prepares for ExuA Launch

- For fiscal year 2025, Aytu BioPharma reported **net revenue of $66.4 million**, a slight increase from the previous year, and achieved its **third consecutive year of positive adjusted EBITDA at $9.2 million**.  **[1385818_2154553_1]** **[1385818_2154553_6]** **[1385818_2154553_7]**  The company's net loss for the full year was **$13.6 million**.  **[1385818_2154553_6]** 
- Aytu BioPharma is preparing for the launch of **Exua**, an FDA-approved, novel, first-in-class treatment for Major Depressive Disorder (MDD) in an over **$22 billion U.S. market**.  **[1385818_2154553_1]** **[1385818_2154553_2]**  Product availability is expected by the **end of calendar year 2025**, with an anticipated investment of approximately **$10 million** in fiscal year 2026 for the initial launch.  **[1385818_2154553_2]** **[1385818_2154553_8]** 
- In its ADHD portfolio, the company launched an **authorized generic of Adzenys on September 2, 2025**, in response to Teva's potential market entry.  **[1385818_2154553_4]**  The ADHD portfolio generated **$57.6 million** in net revenue for fiscal year 2025.  **[1385818_2154553_6]** 
- The company has undergone a strategic pivot, focusing on its prescription pharmaceutical business, which has resulted in a new cost structure projecting an annual expense of **$36.3 million** and a break-even level for its base business of approximately **$52.6 million annually**.  **[1385818_2154553_1]** **[1385818_2154553_6]**

AYTU BioPharma Reports Fiscal Year 2025 Results and Prepares for Exua Launch

- Aytu BioPharma reported **net revenue of $66.4 million** for fiscal year 2025, a 2% increase from the prior year, with a **net loss of $13.6 million** and **adjusted EBITDA of $9.2 million**.  **[1385818_0001437749-25-029721_ex_818415.htm:0]** 
- For the fourth quarter of fiscal 2025, **net revenue increased 4% to $15.1 million**, while the company reported a **net loss of $19.8 million** and **adjusted EBITDA of $2.0 million**.  **[1385818_0001437749-25-029721_ex_818415.htm:0]** 
- The company plans to launch **EXXUA** (gepirone) extended-release tablets in the **fourth calendar quarter of 2025**, targeting the over **$22 billion** United States prescription major depressive disorder market.  **[1385818_0001437749-25-029721_ex_818415.htm:0]** 
- Aytu BioPharma held **$31.0 million** in cash and cash equivalents as of June 30, 2025.  **[1385818_0001437749-25-029721_ex_818415.htm:0]**

AYTU BIOPHARMA (AYTU)